Management of psychosis associated with a prolactinoma: Case report and review of the literature

Psychosomatics

Volumn 51, Issue 5, 2010, Pages 370-376

  Ali, Shirin ^a   Miller, Karen Klahr ^a   Freudenreich, Oliver ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; HALOPERIDOL; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; THYROTROPIN; ZIPRASIDONE;

ADULT; AMENORRHEA; CASE REPORT; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; GALACTORRHEA; HALLUCINATION; HEADACHE; HORMONE SYNTHESIS; HUMAN; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INSOMNIA; MALE; MOOD CHANGE; NAUSEA; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PATHOLOGICAL GAMBLING; PREMENOPAUSE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; VALVULAR HEART DISEASE; VISUAL FIELD; VOMITING;

EID: 77957344311     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1176/appi.psy.51.5.370     Document Type: Review

References (40)

1. Gilliam MP, Molitch ME, Lombard G, et al: Advances in treatment of prolactinomas. Endocr Rev 2006; 27:485-534
2. Schlechte JA: Prolactinoma. N Engl J Med 2003; 349:2035-2041
3. Melmed S, Jameson JL: Disorders of the Anterior Pituitary and Hypothalamus, in Harrison's Principles of Internal Medicine, 17th Edition, Chap. 333. Edited by Fauci AS, Braunwald E, Kasper DL, et al. (The McGraw-Hill Companies, Inc., publisher). Accessed in http://www.accessmedicine.com.ezp- prod1.hul.harvard.edu/pqjcontent.aspx?aID=2876725
4. Zahajszky J, Quinn DK, Smith FA, et al: Cognitive and perceptual disturbances in a young man. Prim Care Companion J Clin Psychiatry 2007; 9:59-63 (Pubitemid 46280280)
5. Szarfman A, Tonning JM, Levine JG, et al: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26:748-758 (Pubitemid 43807626)
6. Daradkeh TK, Ajlouni KM: The effect of neuroleptics on prolactinoma growth in a Jordanian schizophrenic girl. Acta Psychiatr Scand 2008; 77:223-229
7. Weingarten JC, Thompson TL: The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry 1985; 7:364-366
8. Melkersson K, Hulting AL: Prolactin-secreting pituitary adenoma in neuroleptic-treated patients with psychotic disorder. Eur Arch Psychiatry Clin Neurosci 2000; 250:6-10 (Pubitemid 30326366)
9. Pal JK, Sarino WA: Effect of risperidone on prolactinoma growth in a psychotic woman. Psychosom Med 2000; 62:736-738
10. Konopelska S, Quinkler M, Strasburger CJ, et al: Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia: a case report with review of the literature. J Clin Psychopharmacol 2008; 28:120-121
11. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinemia. Drugs 2004; 64:2291-2314
12. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotics in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
13. Montgomery J, Winterbottom E, Jessani M, et al: Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004; 65:1491-1498
14. Melkersson K: Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2004; 66:761-767
15. Zhang XY, Zhou DF, Cao LY, et al: Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology 2005; 178:35-40
16. Sonino N, Tomba E, Fava GA: Psychosocial approach to endocrine disease. Adv Psychosom Med 2007; 28:21-33
17. Sobrinho LG: Emotional aspects of hyperprolactinemia. Psychother Psychosom 1998; 67:133-139
18. Klibanski, Neer RM, Beitins IZ, et al: Decreased bone density in hyperprolactinemic women. N Engl J Med 1980; 303:1511-1514
19. Greenspan SL, Neer RM, Ridgway EC, et al: Osteoporosis in men with hypoprolactinemic hypogonadism. Ann Intern Med 1986; 104:777-782
20. Colao A, Disarno A, Cappabianca P, et al: Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349:2023-2033
21. Brunton LB (Ed.): Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition. New York, McGraw-Hill, Inc, 2006, chap. 55, pp 1498-1501
22. Chang S, Chen C, Lu M: Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008; 30:378-380
23. Zannettini R, Antonini A, Gatto G, et al: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39-46
24. Vallette S, Serri K, Rivera J, et al: Long term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2008; 1386-1341
25. Colao A, Galderisi M, DiSarno A, et al: Increased prevalence of tricuspid regurgitation in patients chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93:3777-3784
26. Devin JK, Lakhani VT, Byrd BF 3rd, et al: Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 2008; 14:672-677
27. Lancellotti P, Livadariu E, Markov M, et al: Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008; 159:1-5
28. Bogazzi F, Buralli S, Manetti L, et al: Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int J Clin Pract 2008; 62:1864-1869
29. Kars M, Pereira A, Bax J, et al: Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 2008; 159:363-367
30. Wakil A, Rigby A, Clark A, et al: Low-dose cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008; 159:R11-R14
31. Robbins RJ, Kern PA Thompson TL: Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma. Am J Med 1984; 76:921-923
32. Byerly M, Suppes T, Tran QV, et al: Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007; 27:639-661
33. Mendhekar DM, Andrade C: Galactorrhea with aripiprazole (letter). Can J Psychiatry 2005; 50:243
34. Ruffatti A, Minervini L, Romano M, et al: Galactorrhea with aripiprazole. Psychother Psychosom 2005; 74:391-392
35. Shim J, Shin J, Kelly D, et al: Adjunctive treatment with a dopamine partial agonist aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164:1404-1410
36. Miller KK: Management of hyperprolactinemia in patients receiving antipsychotics. Neuroendocrine Clinical Center Bulletin 2004; 10:Spring/Summer 2004
37. Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349
38. Citrome L: Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2008; 22(2:suppl):90-97
39. Montastruc JL, Schmitt L, Bagheri H: Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine. Rev Neurol 2003; 4:441-443
40. McGrath PJ, Quitkin FM, Klein DF: Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol 1995; 15: 289-291